Ameritas Investment Partners, Inc. Inozyme Pharma, Inc. Transaction History
Ameritas Investment Partners, Inc.
- $2.98 Billion
- Q4 2024
A detailed history of Ameritas Investment Partners, Inc. transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 4,805 shares of INZY stock, worth $6,582. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,805
Previous 4,805
-0.0%
Holding current value
$6,582
Previous $25,000
48.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding INZY
# of Institutions
103Shares Held
50.7MCall Options Held
2.6KPut Options Held
5.1K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.16MShares$7.07 Million0.03% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$6.16 Million11.45% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$5.86 Million0.97% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.97MShares$5.44 Million1.97% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.86MShares$5.29 Million0.43% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $55M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...